Physiomics awarded further contracts with Merck

Oncology drug development consultancy Physiomics said on Friday that it had been awarded two further contracts by existing client Merck.

Physiomics said the contracts, expected to be completed by the end of 2021, involved simulations of the clinical efficacy of drug products in Merck's DNA damage/repair portfolio.

Chief executive Dr Jim Millen said: "Merck remains a key, valued client and we are pleased to be continuing to work with them on a number of important development programs."

As of 0910 BST, Physiomics shares were down 0.66 at 6.06p.